AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AGENUS INC Director's Dealing 2010

Oct 28, 2010

34023_dirs_2010-10-28_627bfe8f-3920-45f1-83c9-55bc80134a41.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ANTIGENICS INC /DE/ (AGEN)
CIK: 0001098972
Period of Report: 2010-10-26

Reporting Person: Wentworth Kerry (VP, Clin, Reg & Quality)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2010-10-26	Common Stock	A	4165	$0.98	Acquired	148253	Direct
2010-10-26	Common Stock	S	4165	$0.97	Disposed	144088	Direct

Footnotes

F1: Represents settlement of restricted stock awarded on January 26, 2010.

F2: Represents sale of shares obtained from the vesting of the restricted stock awarded on January 26, 2010. This sale was made through a 10b5-1 trading plan.